Videos
Press Releases
2 Feb 2021
PRESS RELEASE: EORTC 1945 OligoRARE trial in oligometastatic rare cancers receives support by Anticancer Fund & Rising Tide Foundation
20 Jan 2021
PRESS RELEASE: First Patients Tested with InVisionFirst®-Lung in EORTC Sponsored Phase II NSCLC Study
19 Sep 2020
PRESS RELEASE: KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Compared Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma
16 Jul 2020
PRESS RELEASE: Advocacy Organizations and Professional Societies from Across the Globe Unite on Brain Tumour Patients’ Charter of Rights
Latest Newsletter
News
25 Oct 2024
Do regulations and policies undermine the social value of independent academic research?
10 Oct 2024
EORTC Quality of Life Group’s participation to ISOQOL 2024
8 Oct 2024
New Insights into Glioblastoma Treatment for Older Adults Patients
24 Sep 2024
TOPGEAR trial results show no significant benefit of preoperative chemoradiotherapy on long term survival
17 Sep 2024
Breast Cancer Group,Genito-Urinary Cancers Group,Head and Neck Cancer Group,Lung Cancer Group,Melanoma Group,News
New results and forthcoming EORTC trials in prostate cancer, melanoma, head and neck, lung, rare, and breast cancers presented at ESMO 2024
16 Sep 2024
Late Breaking Results from the EORTC 1333/PEACE III phase III trial
10 Sep 2024
EORTC’s presence at ESMO 2024
9 Jul 2024
Meet the new EORTC Board
17 Jun 2024
We are pleased to announce the release of the EORTC 2023 Annual Report
